IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Based on management’s discussion, the “Scent” recovery is being driven by three interlocking factors: (1) stabilization and gradual rebound in Fine Fragrance, (2) Consumer Fragrance rebuilding via R&D capability + go-to-market focus to win back share, and (3) strong performance and mix shift within Fragrance Ingredients (including normalization expectations after Q2 strength).
Management attributes Fine Fragrance resilience to active management of Middle East-related uncertainty, including maintaining performance despite volatility. In Q2, the team “did a very good job at managing the challenges in the Middle East,” resulting in Fine Fragrance finishing “up slightly positive” versus expectations of “down in Fine Fragrance mid-single digits” heading into the quarter 1.
They also describe the path as: “softer Q3” followed by “recovery…as we get to Q4” while considering that Q3 last year was a very strong comp (“Fine Fragrance grew 20%…year-over-year in Q3 last year”) 1.
Management explicitly links Consumer Fragrance improvement to rebuilding R&D capability and strengthening the commercial execution with customers to drive market share gains. They say the team has done “a good job on the compounds” and is “rebuild[ing] the R&D capability [and] go-to-market approach with customers, and trying to drive market share gains” 2.
This matters because it indicates the recovery is not just cyclical; it is supported by internal capability restoration (R&D pipeline + customer-facing commercialization) 2.
The near-term “Scent” recovery momentum is supported by double-digit growth in Fragrance Ingredients, which also boosted the overall Scent segment in Q2. Scent Q2 sales were up 8% with a “key driver” being Fragrance Ingredients that “grew north of 20%” 1. Additionally, in the segment overview, “Scent delivered sales of $665 million, representing a strong 8% growth,” “performance was driven by double-digit growth in Fragrance Ingredients” 3.
However, management expects normalization because Q2 benefited from both comparison effects and a temporary mix toward synthetics. They explain Q2 Fragrance Ingredients growth was partly due to “comparing to a down 10% or more in the year ago period,” and partly because they “strategically leveraged the synthetics portfolio” to capture sales amid “macro…supply chain disruptions and higher Brent crude prices” 1.
They also state that as conditions settle, growth “will normalize…included in our forecast for the second half of the year,” shifting “back towards the higher value-added ingredients versus the traditional synthetics” 1.
In Q2, Scent performance is described as both growing and improving profitably. Scent sales increased 8% 3, and Scent EBITDA grew 5% to $134 million, with “volume growth and productivity gains” cited as primary drivers 3. This aligns with the broader theme that the recovery is being supported by execution and productivity, not only top-line rebound 3.
Management provides a directional “growth-rate” outlook for the second half, plus qualitative notes about volatility, comps, and normalization.
They explicitly characterize Fine Fragrance as:
They further connect the timing to difficult prior-year comps and continued Middle East uncertainty: Q3 is pressured partly by a “20% comparable” from Q3 last year, while recovery becomes more visible by Q4 1.
Interpretation grounded in management’s framing: Fine Fragrance recovery is present, but its visibility is delayed by (i) Middle East-related uncertainty and (ii) cycling a very strong prior-year quarter, making Q3 weaker and Q4 comparatively stronger 21.
Management describes Consumer Fragrance as:
They also flag that while the Consumer Fragrance R&D and go-to-market rebuilding is underway, there is some normalization pressure likely tied to the maturity of the recovery initiatives and the post-Q2 comparison base 2.
Although the question focuses on Fine vs Consumer Fragrance, management also notes Fragrance Ingredients is expected to normalize “and…slightly under pressure in terms of year-over-year performance” as it shifts away from the Q2-driven synthetics strength 21. They also say normalization is “included in our forecast for the second half of the year” 1.
Management’s R&D plan is described in two layers: (1) current capability/pipeline status and (2) how R&D will be used to strengthen competitive position over time (including 2027).
Erik states management is “really pleased” with progress after a prior shortfall: “2.5 years ago…pipeline…was not what it should have been,” but “today…we’ve got a very strong R&D capability,” a “great R&D team,” “great perfumers,” and “a great pipeline of molecules as well as delivery systems” 4.
This directly supports the idea that R&D is no longer the bottleneck; it is being positioned as a driver of differentiated products for both Fine and Consumer Fragrances 4.
Management links the current transition in Fragrance Ingredients (toward “higher-value natural products”) to a time horizon where competitive positioning improves beyond the current year: “that will take a little bit more time…not in the second half of this year. But as we go into next year and the year after, we believe we’ll have a really strong competitive position” 2.
While that statement explicitly references Fragrance Ingredients’ shift to higher-value naturals, it also reflects the broader R&D-to-portfolio evolution cycle (investment now, benefit later) 2. Given the question asks about supporting 2027, this “next year and the year after” framing is the closest provided timeline anchor to 2027 readiness 2.
The recovery plan for Consumer Fragrance specifically includes “rebuild the R&D capability” plus “go-to-market approach with customers” aimed at market share gains 2. This suggests R&D is not treated as lab-only—it is paired with customer deployment and commercialization execution, which is typically necessary for medium-term (including 2027) share gains to materialize 2.
Management emphasizes optimism but also that they “still have a lot more work to do” even while pipeline and capability are stronger 4. This matters for “plan to support 2027” because it implies R&D support is ongoing capability-building rather than a one-time fix 4.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi